Validation of Inflammatory Prognostic Biomarkers in Pleural Mesothelioma
Authors:
- Stephanie IserSIStephanie Iser
- Sarah HintermairSHSarah Hintermair
- Alexander VargaAVAlexander Varga
- Ali ÇelikAÇAli Çelik
- Muhammet SayanMSMuhammet Sayan
- Aykut KankoçAKAykut Kankoç
- Nalan AkyürekNANalan Akyürek
- Betül ÖğütBÖBetül Öğüt
- Pietro BertoglioPBPietro Bertoglio
- Enrico CapozziECEnrico Capozzi
- Piergiorgio SolliPSPiergiorgio Solli
- Luigi VenturaLVLuigi Ventura
Open Access
Abstract
Evoked from asbestos-induced inflammation, pleural mesothelioma represents a fatal diagnosis. Therapy ranges from nihilism to aggressive multimodality regimens. However, it is still unclear who ultimately benefits from which treatment. We aimed to re-challenge inflammatory-related biomarkers’ prognostic value in times of modern immune-oncology and lung-sparing surgery. The biomarkers (leukocytes, hemoglobin, platelets, neutrophils, lymphocytes, monocytes, neutrophil–lymphocyte ratio (NLR), lymphocyte–monocyte ratio (LMR), platelet–lymphocyte ratio (PLR), C-reactive protein (CRP)) and clinical characteristics (age, sex, histology, therapy) of 98 PM patients were correlated to overall survival (OS). The median OS was 19.4 months. Significant OS advantages (Log-Rank) were observed in multimodal treatment vs. others (26.1 vs. 7.2 months, p < 0.001), surgery (pleurectomy/decortication) vs. no surgery (25.5 vs. 3.8 months, p < 0.001), a high hemoglobin level (cut-off 12 g/dL, 15 vs. 24.2 months, p = 0.021), a low platelet count (cut-off 280 G/L, 26.1 vs. 11.7 months, p < 0.001), and a low PLR (cut-off 194.5, 25.5 vs. 12.3 months, p = 0.023). Histology (epithelioid vs. non-epithelioid, p = 0.002), surgery (p = 0.004), CRP (cut-off 1 mg/dL, p = 0.039), and platelets (p = 0.025) were identified as independent prognostic variables for this cohort in multivariate analysis (Cox regression, covariates: age, sex, histology, stage, CRP, platelets). Our data verified the previously shown prognostic role of systemic inflammatory parameters in patients treated with lung-sparing surgery within multimodality therapy.Keywords
Funding Information
- karl landsteiner university of health sciences
This publication has 30 references indexed in Scilit:
- The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidenceExpert Review of Respiratory Medicine, 2016
- Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?Therapeutics and Clinical Risk Management, 2016
- Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural MesotheliomaJournal of Thoracic Oncology, 2016
- Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patientsTumor Biology, 2016
- Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapyRadiation Oncology, 2015
- Relationship Between Prognosis and Neutrophil: Lymphocyte and Platelet:Lymphocyte Ratios in Patients with Malignant Pleural MesotheliomasAsian Pacific Journal of Cancer Prevention, 2014
- Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesisThe Journal of Thoracic and Cardiovascular Surgery, 2013
- Prognostic factors for malignant pleural mesotheliomaCurrent Pulmonology Reports, 2013
- Pretreatment Serum C-Reactive Protein Levels Predict Benefit From Multimodality Treatment Including Radical Surgery in Malignant Pleural MesotheliomaAnnals of Surgery, 2012
- Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2009